PMID: 16502584Mar 1, 2006Paper

Diagnosis and monitoring of CBFB-MYH11-positive acute myeloid leukemia by qualitative and quantitative RT-PCR

Methods in Molecular Medicine
Bert A van der Reijden, Joop H Jansen

Abstract

During the last decade, many mutations present in myeloid leukemias have been molecularly characterized. Several of these mutations have clear prognostic impact. The molecular screening of these mutations has now become an essential part in several risk-adapted international clinical trials. Here we describe protocols for the qualitative and quantitative detection of leukemic cells that are characterized by a CBFB-MYH11 gene fusion.

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andrea CorbaciogluK Döhner
Journal of Hematotherapy & Stem Cell Research
Bjørn Tore GjertsenØystein Bruserud
The Hematology Journal : the Official Journal of the European Haematology Association
Bert A van der ReijdenJ H Jansen
© 2021 Meta ULC. All rights reserved